Showing 8 posts of 8 posts found.

Takeda and ImmunoGen collaborate for development and commercialisation of Elahere in Japan

August 29, 2023
Sales and Marketing Elahere, Immunogen, Oncology, Takeda

ImmunoGen has announced that it has entered into an exclusive collaboration with Takeda Pharmaceutical Company for the development and commercialisation …


ImmunoGen to axe 220 positions as part of new restructuring strategy

June 28, 2019
Manufacturing and Production, Medical Communications Immunogen, pharma

ImmunoGen has announced that, following an in-depth operational review to “extend the company’s cash runway”, it will be implemented a …

Isatuximab improves on standard of care treatments for multiple myeloma

June 3, 2019
Sales and Marketing Cancer, Immunogen, Sanofi, isatuximab, multiple myeloma, pharma

Sanofi and ImmunoGen’s isatuximab combination therapy prolonged progression free survival by five months compared to standard of care treatments in …


ImmunoGen shares plummet by 32% after FDA recommends new Phase 3 trial

May 16, 2019
Business Services, Research and Development Cancer, Immunogen, Shares, ovarian cancer, pharma, stocks

Shares in ImmunoGen fell 32% in premarket trading after the firm said the FDA had recommended a new Phase 3 …


Investigational ImmunoGen drug gives hope against platinum-resistant ovarian cancer

April 20, 2017
Research and Development Cancer, Immunogen, ovarian cancer

Research from GlobalData has suggested that an investigational drug from ImmunoGen could prove effective in treating platinum-resistant ovarian cancer, an …

Takeda image

Takeda buys license to ImmunoGen cancer tech

March 24, 2015
Research and Development, Sales and Marketing ADC, Immunogen, Takeda, antibody, conjugate, merger

Takeda has licensed the exclusive rights to use ImmunoGen’s popular antibody-drug conjugate (ADC) technology to develop new cancer drugs. The …

Roche image

ImmunoGen stops cancer trial

November 6, 2013
Research and Development, Sales and Marketing Cancer, IMGN901, Immunogen, Roche

Roche subsidiary ImmunoGen has abandoned a Phase II trial into small-cell lung cancer (SCLC) after deciding that it was not …

Lilly teams up with ImmunoGen on antibody-drug conjugates

December 21, 2011
ADC, Cancer, Immunogen, T-DM1, conjugate, lilly, oncology

ImmunoGen has signed a new collaboration with Eli Lilly to develop antibody-drug conjugate for cancer treatments.Lilly will pay an upfront …

Latest content